2.13
+0.015(+0.71%)
Currency In USD
| Previous Close | 2.12 |
| Open | 2.11 |
| Day High | 2.27 |
| Day Low | 2.11 |
| 52-Week High | 3.9 |
| 52-Week Low | 0.73 |
| Volume | 276,317 |
| Average Volume | 583,636 |
| Market Cap | 134.81M |
| PE | -2.96 |
| EPS | -0.72 |
| Moving Average 50 Days | 1.54 |
| Moving Average 200 Days | 1.84 |
| Change | 0.02 |
If you invested $1000 in Galectin Therapeutics Inc. (GALT) 10 years ago, it would be worth $812.98 as of July 01, 2025 at a share price of $2.13. Whereas If you bought $1000 worth of Galectin Therapeutics Inc. (GALT) shares 5 years ago, it would be worth $684.89 as of July 01, 2025 at a share price of $2.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension
GlobeNewswire Inc.
Jun 10, 2025 12:56 PM GMT
NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will host a vi
Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress
GlobeNewswire Inc.
May 12, 2025 12:00 PM GMT
Data presentation included efficacy and biomarker analyses from the NAVIGATE trial (n=287). Belapectin 2 mg/kg demonstrated a statistically significant reduction in new varices at 18 months in the per-protocol population (p=0.04). Significantly fewer
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress
GlobeNewswire Inc.
Apr 15, 2025 12:00 PM GMT
NORCROSS, Ga., April 15, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will attend t